PURPOSE: To test the feasibility of salvage radiotherapy using PET-guided helical tomotherapy in patients with progressive malignant pleural mesothelioma (MPM). PATIENTS AND METHODS: A group of 12 consecutive MPM patients was treated with 56 Gy/25 fractions to the planning target volume (PTV); FDG-PET/CT simulation was always performed to include all positive lymph nodes and MPM infiltrations. Subsequently, a second group of 12 consecutive patients was treated with the same dose to the whole pleura adding a simultaneous integrated boost of 62.5 Gy to the FDG-PET/CT positive areas (BTV). RESULTS: Good dosimetric results were obtained in both groups. No grade 3 (RTOG/EORTC) acute or late toxicities were reported in the first group, while 3 cases of grade 3 late pneumonitis were registered in the second group: the duration of symptoms was 2-10 weeks. Median overall survival was 8 months (1.2-50.5 months) and 20 months (4.3-33.8 months) from the beginning of radiotherapy, for groups I and II, respectively (p=0.19). A significant impact on local relapse from radiotherapy was seen (median time to local relapse: 8 vs 17 months; 1-year local relapse-free rate: 16% vs 81%, p=0.003). CONCLUSIONS: The results of this pilot study support the planning of a phase III study of combined sequential chemoradiotherapy with dose escalation to BTV in patients not able to undergo resection.
PURPOSE: To test the feasibility of salvage radiotherapy using PET-guided helical tomotherapy in patients with progressive malignant pleural mesothelioma (MPM). PATIENTS AND METHODS: A group of 12 consecutive MPM patients was treated with 56 Gy/25 fractions to the planning target volume (PTV); FDG-PET/CT simulation was always performed to include all positive lymph nodes and MPM infiltrations. Subsequently, a second group of 12 consecutive patients was treated with the same dose to the whole pleura adding a simultaneous integrated boost of 62.5 Gy to the FDG-PET/CT positive areas (BTV). RESULTS: Good dosimetric results were obtained in both groups. No grade 3 (RTOG/EORTC) acute or late toxicities were reported in the first group, while 3 cases of grade 3 late pneumonitis were registered in the second group: the duration of symptoms was 2-10 weeks. Median overall survival was 8 months (1.2-50.5 months) and 20 months (4.3-33.8 months) from the beginning of radiotherapy, for groups I and II, respectively (p=0.19). A significant impact on local relapse from radiotherapy was seen (median time to local relapse: 8 vs 17 months; 1-year local relapse-free rate: 16% vs 81%, p=0.003). CONCLUSIONS: The results of this pilot study support the planning of a phase III study of combined sequential chemoradiotherapy with dose escalation to BTV in patients not able to undergo resection.
Authors: Yee C Ung; Edward Yu; Conrad Falkson; Adam E Haynes; Denise Stys-Norman; William K Evans Journal: Radiother Oncol Date: 2006-07-03 Impact factor: 6.280
Authors: Florian Sterzing; Gabriele Sroka-Perez; Kai Schubert; Marc W Münter; Christian Thieke; Peter Huber; Jürgen Debus; Klaus K Herfarth Journal: Radiother Oncol Date: 2008-01-18 Impact factor: 6.280
Authors: D J Sugarbaker; R M Flores; M T Jaklitsch; W G Richards; G M Strauss; J M Corson; M M DeCamp; S J Swanson; R Bueno; J M Lukanich; E H Baldini; S J Mentzer Journal: J Thorac Cardiovasc Surg Date: 1999-01 Impact factor: 5.209
Authors: D B Schneider; C Clary-Macy; S Challa; K C Sasse; S H Merrick; R Hawkins; G Caputo; D Jablons Journal: J Thorac Cardiovasc Surg Date: 2000-07 Impact factor: 5.209
Authors: Victor H Gerbaudo; David J Sugarbaker; Scott Britz-Cunningham; Marcelo F Di Carli; Charles Mauceri; S Ted Treves Journal: J Nucl Med Date: 2002-09 Impact factor: 10.057
Authors: A Botticella; G Defraene; K Nackaerts; C Deroose; J Coolen; P Nafteux; B Vanstraelen; S Joosten; L A W Michiels; S Peeters; D De Ruysscher Journal: Strahlenther Onkol Date: 2017-02-14 Impact factor: 3.621
Authors: B Henriques de Figueiredo; T Merlin; H de Clermont-Gallerande; M Hatt; D Vimont; P Fernandez; F Lamare Journal: Strahlenther Onkol Date: 2013-11-01 Impact factor: 3.621
Authors: C Lütgendorf-Caucig; I Fotina; E Gallop-Evans; L Claude; J Lindh; T Pelz; B Knäusl; D Georg; R Pötter; K Dieckmann Journal: Strahlenther Onkol Date: 2012-10-10 Impact factor: 3.621
Authors: E Incerti; S Broggi; A Fodor; M Cuzzocrea; A M Samanes Gajate; P Mapelli; C Fiorino; I Dell'Oca; M Pasetti; M Cattaneo; R Calandrino; L Gianolli; N Di Muzio; Maria Picchio Journal: Eur J Nucl Med Mol Imaging Date: 2018-06-06 Impact factor: 9.236